Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Clinical trial NCT07385703 · RECRUITING
Trial details
- NCT number
- NCT07385703
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-15
- Primary completion
- 2028-10-01
- Enrollment
- 752
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.